Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer

被引：38

作者：

Bay, JO

Choufi, B

Pomel, C

Dauplat, J

Durando, X

Tournilhac, O

Travade, P

Plagne, R

Blaise, D

机构：

[1] Ctr Jean Perrin, Unite Transplantat Medullaire, F-63011 Clermont Ferrand, France

[2] Ctr Jean Perrin, Dept Chirurg, F-63011 Clermont Ferrand, France

[3] CHU Clermont Ferrand, Hotel Dieu, Serv Hematol, Clermont Ferrand, France

[4] Inst J Paoli I Calmettes, Unite Transplant & Therapie Cellulaire, F-13009 Marseille, France

来源：

BONE MARROW TRANSPLANTATION | 2000年 / 25卷 / 06期

关键词：

ovarian cancer; allograft transplantation; graft-versus-host disease;

D O I：

10.1038/sj.bmt.1702206

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

A 33-year-old woman developed progressive ovarian cancer resistant to classical chemotherapy agents. We performed a bone marrow allograft after a myeloablative regimen. During hematological recovery, she developed acute graft-versus-host disease (GVHD). From this time her tumor diminished progressively. One year post transplant she has limited chronic liver GVHD and is still free of disease. The complete remission of advanced ovarian cancer was probably related to the GVHD which might therefore provide a new treatment option for this disease.

引用

页码：681 / 682

页数：2

共 6 条

[1] Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia [J].

BenYosef, R ;

Or, R ;

Nagler, A ;

Slavin, S .

LANCET, 1996, 348 (9036) :1242-1243

[2] Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect [J].

Childs, RW ;

Clave, E ;

Tisdale, J ;

Plante, M ;

Hensel, N ;

Barrett, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2044-2049

[3] New non-cytotoxic approaches to ovarian cancer [J].

Kaye, SB ;

Eisenhauer, EA ;

Hamilton, TC .

ANNALS OF ONCOLOGY, 1999, 10 :65-68

[4] High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results [J].

Legros, M ;

Dauplat, J ;

Fleury, J ;

Cure, H ;

Suzanne, F ;

Chassagne, J ;

Bay, JO ;

Sol, C ;

Canis, M ;

Condat, P ;

Choufi, B ;

Tavernier, F ;

Glenat, C ;

Chollet, P ;

Plagne, R .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1302-1308

[5] Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].

Slavin, S ;

Nagler, A ;

Naparstek, E ;

Kapelushnik, Y ;

Aker, M ;

Cividalli, G ;

Varadi, G ;

Kirschbaum, M ;

Ackerstein, A ;

Samuel, S ;

Amar, A ;

Brautbar, C ;

Ben-Tal, O ;

Eldor, A ;

Or, R .

BLOOD, 1998, 91 (03) :756-763

[6] Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer [J].

Ueno, NT ;

Rondón, G ;

Mirza, NQ ;

Geisler, DK ;

Anderlini, P ;

Giralt, SA ;

Andersson, BS ;

Claxton, DF ;

Gajewski, JL ;

Khouri, IF ;

Körbling, M ;

Mehra, RC ;

Przepiorka, D ;

Rahman, Z ;

Samuels, BI ;

van Besien, K ;

Hortobagyi, GN ;

Champlin, RE .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :986-993

← 1 →